AstraZeneca stock: Klygefa wins US and EU approvals
Published on 11/16/2026 at 17:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey developments for investors
- Klygefa received US and EU approvals for adults with AChR-positive generalised myasthenia gravis.
- The PREVAIL Phase III trial showed a statistically significant improvement in daily-living activities.
- AstraZeneca stock traded at 168.10 euros on Lang & Schwarz on Monday afternoon.
AstraZeneca announced on Monday, November 16, 2026, that Klygefa (gefurulimab) had been approved in the United States and the European Union for adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis. The company described the medicine as the first approved dual-binding nanobody C5 inhibitor in both markets, according to its US release and EU release.
Approvals expand rare-disease reach
The US Food and Drug Administration approval covers adults with generalised myasthenia gravis who are anti-acetylcholine receptor antibody positive. The European Commission approved Klygefa as an add-on to standard therapy for the same patient group.
The approvals were based on the PREVAIL Phase III trial. AstraZeneca said the study met its primary endpoint, with a treatment difference of -1.6 in the Myasthenia Gravis Activities of Daily Living score at week 26 compared with placebo. Clinical improvement was observed from week one and continued through week 26.
Once-weekly administration
Klygefa is designed for once-weekly subcutaneous self-administration through an autoinjector. AstraZeneca said the treatment was generally well tolerated in the trial, while the US release listed injection-site reactions, back pain and vomiting among the most common treatment-emergent adverse events.
AstraZeneca stock traded at 168.10 euros on Lang & Schwarz at 17:40 CET on Monday, November 16, 2026.
AstraZeneca at a glance
- Company: AstraZeneca PLC
- ISIN: GB0009895292
- Quote: 168.10 euros on Lang & Schwarz at 17:40 CET, Monday, November 16, 2026
- Business: Biopharmaceuticals, oncology and rare diseases
The UK market environment can be followed in Current market reports.
More news and analyses on AstraZeneca stock.
